We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
- Authors
Mackey, Katherine; Kansagara, Devan; Vela, Kathryn
- Abstract
This document is an update alert from the Annals of Internal Medicine regarding the risks and impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) on SARS-CoV-2 infection in adults. The update summarizes the current evidence on the benefits and harms of initiating ACEIs or ARBs in adults with COVID-19 who were not previously taking these medications. The review includes the findings from seven trials, which suggest that ARB initiation among adults with COVID-19 probably does not have a mortality benefit and does not change the severity of the disease. However, the trials have limitations, and the results may not be applicable to current and future COVID-19 cases due to factors such as the introduction of vaccines and the emergence of new variants.
- Subjects
ACE inhibitors; ANGIOTENSIN-receptor blockers; SARS-CoV-2; ADULTS; COVID-19
- Publication
Annals of Internal Medicine, 2023, Vol 176, Issue 5, p1
- ISSN
0003-4819
- Publication type
Article
- DOI
10.7326/L23-0049